Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
23.67
+0.04 (+0.17%)
Streaming Delayed Price
Updated: 3:54 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Thera CS
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
December 12, 2023
Intellia is approaching the finish line.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
November 28, 2023
These stocks may take off in a market favoring growth.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
November 17, 2023
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
November 10, 2023
Via
Benzinga
2 Brilliant Growth Stocks to Buy and Hold Forever
October 12, 2023
These two growth stocks could be genuine wealth escalators.
Via
The Motley Fool
Down 45%, Is Intellia a Buy?
October 10, 2023
Intellia's operating in the high-growth field of gene editing.
Via
The Motley Fool
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
Why Intellia Therapeutics Stock Is Surging Tuesday
November 14, 2023
Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d
Via
Benzinga
Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock
November 13, 2023
Via
Benzinga
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
November 06, 2023
Roku vaulted 50% to become Ark Innovation's top holding.
Via
Investor's Business Daily
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
November 02, 2023
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.
Via
The Motley Fool
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
October 28, 2023
There's more to being a good investment than doing groundbreaking science.
Via
The Motley Fool
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
October 23, 2023
The three companies are positioned to benefit from red-hot trends.
Via
The Motley Fool
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
October 21, 2023
Wood is going all in on gene editing.
Via
The Motley Fool
Cathie Wood's Ark Offloads $6.3M In Tesla Shares Amid EV Maker's Q3 Earnings Disappointment
October 18, 2023
Via
Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
October 16, 2023
These two large-cap biopharma companies could have more room to run.
Via
The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
October 14, 2023
These two gene-editing stocks could be diamonds in the rough.
Via
The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
October 11, 2023
Via
Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
October 10, 2023
Via
Benzinga
This Cathie Wood Stock Is Poised to Double, Says Wall Street
October 10, 2023
Almost anything is possible in the volatile biotech industry.
Via
The Motley Fool
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
October 03, 2023
Don't bet the farm on the analysts being right -- but they might be.
Via
The Motley Fool
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
October 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
September 23, 2023
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.
Via
The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.